<DOC>
	<DOCNO>NCT00344383</DOCNO>
	<brief_summary>The purpose study evaluate bleed profile norgestimate/ethinyl estradiol , oral contraceptive tablet , give extend regimen</brief_summary>
	<brief_title>An Open-Label Study Evaluating Breakthrough Bleeding Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered Extended Regimen</brief_title>
	<detailed_description>This open-label study evaluate bleed profile norgestimate/ethinyl estradiol tablet administer extended regimen ( 84 consecutive day active tablet follow seven day medication free ) follow traditional regimen two 28-day cycle ( 21 day active tablet , follow seven day placebo tablet ) norgestimate/ethinyl estradiol tablet . All patient receive norgestimate/ethinyl estradiol tablet traditional regimen two 28-day cycle . Following Traditional Treatment Phase , patient receive norgestimate/ethinyl estradiol tablet Extended Regimen Treatment Phase , consist 84 day treatment norgestimate/ethinyl estradiol tablet . Safety evaluation include physical examination , adverse event report vital sign . The hypothesis study triphasic extend regimen would result breakthrough bleed spot progestin dose drop . Traditional Regimen : two 28 day cycle norgestimate 180 mcg daily 1 week , 215 mcg daily 1 week , 250 mcg daily 1 week , placebo daily 1 week . Extended Regimen : four uninterrupted cycle norgestimate 180 mcg daily 1 week , 215 mcg daily 1 week , 250 mcg daily 1 week , 1 week medication-free . In Treatment Regimens patient receive ethinyl estradiol 25 mcg active tablet . The study 147 day , Traditional day 1-56 Extended day 57-147</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subjects good health confirm medical history , physical exam , PAP smear within precede six month Nonsmokers , 35 45 year age Patients pregnant lactating Had least one normal menstrual period within 35 day prior screen Completed last term pregnancy least 42 day prior screen least one normal menstrual period since last pregnancy Must postmenarcheal ( least one normal menstrual period ) premenopausal ( regular menstrual period ) History presence disorder commonly accept contraindication steroid hormonal therapy , eg , menopause , active history deep vein thrombophlebitis , thromboembolic disorder hypercoagulation disorder , cerebral vascular coronary artery disease , uncontrolled hypertension , migraine focal aura , benign malignant liver tumor develop use oral contraceptive estrogencontaining product carcinoma body system , diabetes mellitus vascular involvement , know suspected estrogendependent neoplasia , cholestatic jaundice , undiagnosed abnormal vaginal bleeding , neurovascular lesion eye , clinically relevant impairment liver function , liver disease renal disease absence cyclic bleeding least three month , recent history alcohol substance abuse significant depression psychiatric disease would result unreliable patient subject deem investigator questionable reliability ability comply protocol provide accurate information .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>breakthrough bleeding</keyword>
	<keyword>spot</keyword>
</DOC>